Abstract
Genetic profiling of tumors has revealed important regulators of the metastatic process and suggested novel targets for cancer therapeutics. Targeting the tumor cell alone is not sufficient; multimodality therapy against tumor cells, their growth factors and the essential accessory cells with which cancer cells interact is imperative. In the bone marrow and within the tumor stroma, two niches constitute highly specific, physiologically defined sites; the vascular and stromal niche. A high preponderance of tumor cells is found in the bone marrow of patients with malignancy, even in the absence of overt distant metastases. Bisphosphonates inhibit normal and pathologic osteoclast-mediated bone resorption. Denosumab inhibits the maturation of osteoclasts by binding to RANKL, protecting the bone from degradation.
| Original language | English |
|---|---|
| Title of host publication | Advances in Bone Metastasis Management |
| Publisher | Future Medicine Ltd. |
| Pages | 19-28 |
| Number of pages | 10 |
| ISBN (Print) | 9781780840307, 9781780841151 |
| DOIs | |
| Publication status | Published - Mar 1 2012 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Metastatic spread to bone : The role of chemotherapy. / Ferrari, Stefano; Palmerini, Emanuela; Mavrogenis, Andreas F.; Ruggieri, Pietro.
Advances in Bone Metastasis Management. Future Medicine Ltd., 2012. p. 19-28.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Metastatic spread to bone
T2 - The role of chemotherapy
AU - Ferrari, Stefano
AU - Palmerini, Emanuela
AU - Mavrogenis, Andreas F.
AU - Ruggieri, Pietro
PY - 2012/3/1
Y1 - 2012/3/1
N2 - Genetic profiling of tumors has revealed important regulators of the metastatic process and suggested novel targets for cancer therapeutics. Targeting the tumor cell alone is not sufficient; multimodality therapy against tumor cells, their growth factors and the essential accessory cells with which cancer cells interact is imperative. In the bone marrow and within the tumor stroma, two niches constitute highly specific, physiologically defined sites; the vascular and stromal niche. A high preponderance of tumor cells is found in the bone marrow of patients with malignancy, even in the absence of overt distant metastases. Bisphosphonates inhibit normal and pathologic osteoclast-mediated bone resorption. Denosumab inhibits the maturation of osteoclasts by binding to RANKL, protecting the bone from degradation.
AB - Genetic profiling of tumors has revealed important regulators of the metastatic process and suggested novel targets for cancer therapeutics. Targeting the tumor cell alone is not sufficient; multimodality therapy against tumor cells, their growth factors and the essential accessory cells with which cancer cells interact is imperative. In the bone marrow and within the tumor stroma, two niches constitute highly specific, physiologically defined sites; the vascular and stromal niche. A high preponderance of tumor cells is found in the bone marrow of patients with malignancy, even in the absence of overt distant metastases. Bisphosphonates inhibit normal and pathologic osteoclast-mediated bone resorption. Denosumab inhibits the maturation of osteoclasts by binding to RANKL, protecting the bone from degradation.
UR - http://www.scopus.com/inward/record.url?scp=84956791415&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84956791415&partnerID=8YFLogxK
U2 - 10.2217/EBO.11.358
DO - 10.2217/EBO.11.358
M3 - Chapter
AN - SCOPUS:84956791415
SN - 9781780840307
SN - 9781780841151
SP - 19
EP - 28
BT - Advances in Bone Metastasis Management
PB - Future Medicine Ltd.
ER -